New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
about
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesMonoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategiesAdvances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaMonoclonal antibodies targeting CD38 in hematological malignancies and beyondDoes my patient with a serum monoclonal spike have multiple myeloma?Smoldering multiple myelomaSmoldering multiple myeloma requiring treatment: time for a new definition?Smoldering multiple myeloma.Immunophenotypic studies of monoclonal gammopathy of undetermined significanceFlow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis.Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaMonoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Myelomagenesis: capturing early microenvironment changesDiagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.How I treat smoldering multiple myeloma.Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.Dilemmas in treating smoldering multiple myeloma.C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia.Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.Molecular pathogenesis of multiple myeloma and its premalignant precursor.Myeloma today: Disease definitions and treatment advances.Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).Multiple myeloma in the marrow: pathogenesis and treatments.Precursors to lymphoproliferative malignancies.Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.Challenges in multiple myeloma diagnosis and treatment.Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology
P2860
Q24604581-F5DFE75C-8C4A-46CC-8D44-7729E4DEBEDCQ24607241-D7E9D96D-D9B0-46EE-B420-BC91ED67AE46Q24619589-E6997C28-A333-4CC3-AF43-1C1E37951022Q26766718-41FB30AF-F11D-4115-BBBB-03E612787725Q26821981-924C4788-A6D3-4B8E-9A5D-35F0ED0FD6ACQ26863331-9E1970CF-3D36-4C6A-B20B-B0156D3A987EQ26996579-FAF0C5BF-8F77-42F8-A84F-8E5719A6F600Q28082855-83E17CF0-429F-456B-B71E-053A4093AB52Q33387979-B9BBC34B-998E-43F3-929D-BCEF586A0D3EQ33598391-A464B5CB-E157-4405-BA89-2BC06EE56086Q33628815-86F34719-6DD3-4E93-95F7-DBB6E961789FQ33695919-7C67D993-7819-400A-9ADE-0D682BE27BF8Q33816012-28E6A398-C38C-474B-900F-79A7B0FA29D9Q34316559-1ADF7C84-640E-4A1F-8DC3-B780BF9FCE45Q34519296-87CE2CEC-7748-4E74-AE8B-A21476033DD1Q34525834-1BDF5C40-8976-4EB8-9A26-582569D46861Q34556156-35A8B405-E76D-487D-BD7D-E88D695BA941Q34557651-67DF17CE-2817-4A3F-B40B-0A611278F39AQ34580094-6EB60B82-3C00-4653-A8C2-B633895E9AA2Q34580260-EA3C893E-DA7C-4E52-B677-E88571FAAC2DQ34716500-644FF96F-B96B-4D92-B16F-92B3509ED1E7Q34936088-5938D953-0626-4AA2-AEE4-6EB956501699Q35143513-5BFBDD24-E583-4F13-AA94-8FB7B89F8BB6Q35664299-3058E8B0-8044-407E-A540-262DD8BA8125Q35669068-9819ED56-B4E5-40BF-8013-4EF5B46B5FD2Q36254248-9BF05CC9-F92C-4F4F-94BE-2FF63CCAECF5Q36290238-985592A2-8D25-4152-9EC8-97F49BFD021FQ36470699-E84431D3-2B84-4CAC-A9FE-0D3DB7B32D42Q36525224-FEB2A974-E89D-4DFA-A9B3-284DA0A12DAFQ36673465-6FF5D15B-CDEE-4C2E-980E-0C6B0AD49C21Q36708969-6B2B6C04-A960-4C8B-9AAF-98FFE8C75210Q36725401-1480AB6F-B5A3-4387-8254-58D38F4D7CBFQ36739877-22B10AFF-1805-4C0A-988A-4D008F623357Q36742324-CB94FF8C-18C6-41EA-A470-7C1549038091Q36777247-380FF4D2-584B-4A0C-A695-D965312D21F3Q36799760-B727096B-4F34-4F7E-B1D6-1983C85ADF4FQ36821228-1ACEA9A1-563F-4040-A153-0FE9E64F9E35Q36852225-5DE6E273-CC68-4065-B117-B1281B47BE2EQ36950805-6F7A27B5-B299-4438-BA8F-7FF5422F3653Q36963203-94D7CA4F-E5D5-4DE7-882C-A16552D18A2A
P2860
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
New criteria to identify risk ...... s of bone marrow plasma cells.
@ast
New criteria to identify risk ...... s of bone marrow plasma cells.
@en
New criteria to identify risk ...... s of bone marrow plasma cells.
@nl
type
label
New criteria to identify risk ...... s of bone marrow plasma cells.
@ast
New criteria to identify risk ...... s of bone marrow plasma cells.
@en
New criteria to identify risk ...... s of bone marrow plasma cells.
@nl
prefLabel
New criteria to identify risk ...... s of bone marrow plasma cells.
@ast
New criteria to identify risk ...... s of bone marrow plasma cells.
@en
New criteria to identify risk ...... s of bone marrow plasma cells.
@nl
P2093
P1433
P1476
New criteria to identify risk ...... s of bone marrow plasma cells.
@en
P2093
Alberto Orfao
Alejandro Martín
Alfonso García de Coca
Consuelo López-Berges
Ernesto Pérez-Persona
Gema Mateo
Guillermo Martín-Nuñez
Jesús F San Miguel
Josefina Galende
José M Alonso
P304
P356
10.1182/BLOOD-2007-05-088443
P407
P577
2007-06-18T00:00:00Z